Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › edoxaban

edoxaban

7 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of edoxaban

14 trials tracked of edoxaban: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 1599 citations.

14Trials tracked
8Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 3 8 Phase 2 2 Other / NA 4
  1. Phase 3 Cancer Venous Thromboembolism (VTE) Completed · 1,599 cited
  2. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 658 cited
  3. Phase 3 Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF) Completed · 246 cited
  4. Phase 3 Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease Completed · 59 cited
  5. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation Completed · 12 cited
  6. Phase 3 Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) Completed
Show 8 more trials
  1. Phase 3 A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Completed
  2. Phase 3 A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty Completed
  3. Phase 2 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects Completed
  4. Phase 2 Edoxaban in Peripheral Arterial Disease Completed
  5. N/A Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea Completed
  6. N/A Medical Need of OAC Reversal Completed
  7. N/A Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe Completed
  8. N/A Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Edoxaban trough concentration and PT predict major bleeding in very old AF patients
Cardiology RCT
Edoxaban trough concentration and PT predict major bleeding in very old AF patients Blood thinner levels linked to bleeding in very old patients
This post hoc analysis of the ELDERCARE-AF RCT included 427 very old Japanese patients with atrial fibrillation and high bleeding risk. High…
Higher edoxaban levels in the blood may increase bleeding risk in patients 80 and older with atrial fibrillation.
May 24, 2026
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk
Cardiology Meta-analysis
Network meta-analysis compares DOACs and VKAs for intracranial hemorrhage risk Dabigatran may be safest for brain bleeding risk
This network meta-analysis of 127,267 patients with venous thromboembolism or atrial fibrillation found that all DOACs had lower risk of int…
All blood thinners beat warfarin for brain bleed risk, but dabigatran may be the safest choice.
Frontiers May 19, 2026
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications
Drug Pipeline Sys. Review
PRISMA Scoping Review Examines Food-Drug Interactions in Cardiovascular and Diabetic Medications Meals May Not Matter for Most New Heart and Diabetes Pills
This PRISMA scoping review synthesized data from 36 publications regarding food-drug interactions in cardiovascular and diabetic medications…
Most new heart and diabetes pills work the same whether you take them with food or on an empty stomach, but a few still need timing.
Frontiers Apr 27, 2026
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis
Cardiology Meta-analysis
Genetic polymorphisms influence pharmacokinetics and bleeding risk for DOACs in meta-analysis Your DNA May Explain Why Blood Thinners Work Differently for You
A meta-analysis of 39 studies involving 13,300 patients found that genetic polymorphisms (e.g., CES1, ABCB1) are associated with pharmacokin…
Tiny DNA differences may explain why the same blood thinner protects one person but causes bleeding in another.
Frontiers Apr 15, 2026
Edoxaban monotherapy reduces adverse events compared to dual therapy in patients with atrial fibrillation and coronary artery disease
Cardiology RCT
Edoxaban monotherapy reduces adverse events compared to dual therapy in patients with atrial fibrillation and coronary artery disease One Blood Thinner May Be Safer Than Two for Heart Rhythm Patients
This secondary analysis of a randomized clinical trial evaluated 1,040 patients with atrial fibrillation and stable coronary artery disease.
Taking just one blood thinner instead of two cuts the risk of death, stroke, or bleeding for heart patients with irregular rhythms.
Apr 9, 2026
DOACs show varied efficacy and safety profiles versus VKAs in atrial fibrillation patients with fall risk
Cardiology Meta-analysis
DOACs show varied efficacy and safety profiles versus VKAs in atrial fibrillation patients with fall risk Study compares blood thinners for atrial fibrillation patients with fall risk
A Bayesian network meta-analysis of 10 studies (5 RCTs, 5 observational) in AF patients with fall history/risk found apixaban ranked highest…
For atrial fibrillation patients at risk of falling, apixaban best prevents strokes while edoxaban best lowers major bleeding risks compared…
Apr 5, 2026
Edoxaban 12 months superior to 3 months for VTE prevention in cancer DVT, regardless of anemia status
Oncology RCT
Edoxaban 12 months superior to 3 months for VTE prevention in cancer DVT, regardless of anemia status For cancer patients with a leg blood clot and anemia, does longer treatment work better?
In this prespecified subgroup analysis of the ONCO DVT study, 12 months of edoxaban was superior to 3 months for preventing symptomatic recu…
Cancer patients with leg clots and anemia get better protection against new clots with 12 months of edoxaban compared to just 3 months, with…
Mar 30, 2026